Mariana C. Castells, MD, AAAAI 22: A Phase 2/3 Study of BLU-263 in Patients with Indolent Systemic Mastocytosis or Monoclonal Mast Cell Activation Syndrome.

It was an absolute pleasure to speak with Prof. Mariana Castells (Brigham and Women’s Hospital, Boston, MA) about her study of BLU-263 and how it is supporting continued development for patients with Indolent Systemic Mastocytosis or Monoclonal Mast Cell Activation Syndrome.

The abstract entitled ‘A Phase 2/3 Study of BLU-263 in Patients with Indolent Systemic Mastocytosis or Monoclonal Mast Cell Activation Syndrome’ (Abstract #665) was presented at The American Academy of Allergy, Asthma & Immunology (AAAAI), February 25-28, 2022

Questions:

1. What is BLU-263 and what is the rationale for its use in this patient population?(0:25)
2. What are the aims and design of the HARBOR study?(02:26)
3. What are the eligibility criteria of the study?(03:51)
4. When are the initial results expected?(05:12)

Disclosures: Mariana Castells has nothing to disclose in relation to this video.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.

Filmed in coverage of the virtual AAAAI 2022.